UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

	,			
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/754,115	01/07/2004	Timothy D. Hey	DAS-104XCI	8974
23557 7590 07/06/2007 SALIWANCHIK LLOYD & SALIWANCHIK			EXAMINER	
A PROFESSIO	ONAL ASSOCIATION		KOSSON, ROSANNE	
PO BOX 142950 GAINESVILLE, FL 32614-2950		•	ART UNIT	PAPER NUMBER
			1652	
•				
			MAIL DATE	DELIVERY MODE
			07/06/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450 ·

Alexandria, Virginia 22313-1450

10/7541115

APPLICATION NO./ FILING DATE FIRST NAMED INVENTOR /
CONTROL NO. PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

EXAMINER

ART UNIT

PAPER

20070627

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on June 19, 2007 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s). None of the amended or new claims reads on the elected invention, a composition comprising an effective amount of a Xenorhabdus A protein, a Photorhabdus B protein and a Photorhabdus C protein, in which the A protein is SEQ ID NO: 34. See 37 CFR 1.111. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rosanne Kosson whose telephone number is 571-272-2923. The examiner can normally be reached on Monday-Friday, 8:30-6:00, alternate Mondays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Rosanne Kosson Examiner, Art Unit 1652

rk/2007-06-27 Kosanne Kosson

RECECCA PARTINER PRIMARY EXPENINER

•	Application No.	Applicant(s)		
Examinar Initiated Intensions Summary	10/754,115	HEY ET AL.		
Examiner-Initiated Interview Summary	Examiner	Art Unit		
	Rosanne Kosson	1652		
Participants: Status of Application: <u>rejected</u>				
(1) <u>Rosanne Kosson</u> .	(3)			
(2) Jay Sanders, Applicants' representatives.	(4)			
Date of Interview:	Time: <u>2 pm</u>			
Type of Interview: ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applic Exhibit Shown or Demonstrated: ☐ Yes ☐ No If Yes, provide a brief description:	ant's representative)			
Part I.	•			
Rejection(s) discussed:				
Claims discussed: those pending				
Prior art documents discussed: none	40			
Part II.				
SUBSTANCE OF INTERVIEW DESCRIBING THE GENE See Continuation Sheet	RAL NATURE OF WHAT WA	S DISCUSSED:		
Part III.	•			
 It is not necessary for applicant to provide a separate directly resulted in the allowance of the application. The of the interview in the Notice of Allowability. It is not necessary for applicant to provide a separate did not result in resolution of all issues. A brief summar 	e examiner will provide a writt record of the substance of the	ten summary of the substance interview, since the interview		
Rosam Kosson				
	t/Applicant's Representative S	ignature – if appropriate)		

Continuation of Substance of Interview including description of the general nature of what was discussed: Applicants' representative was informed that, in the amended claim set filed on 6/19/07, none of the claims read on the elected invention- an insecticidal composition of a homotetramer of an A protein (recited in the claims as an effective amount of an A protein), a B protein and a C protein in which the A protein is SEQ ID NO: 34 (from Xenorhabdus), the B protein is one definite and specific protein from a set of Photorhabdus B proteins that enhance the insecticidal activity of SEQ ID NO: 34, and the C protein is one definite and specific protein from a set of Photorhabdus C proteins that enhance the insecticidal activity of SEQ ID NO: 34. In addition to reciting non-elected sequences, the "wherein" clauses change the meaning of the claims, because they recite that when B is from Xenorhabdus, C is from Photorhabdus and visa versa. Applicants' representative was advised that he would receive a notice of incomplete response. Applicants' representative will file an amended claim set in response to this notice.